Quality of life and costs of patients prior to colorectal surgery.
This study is a quantitative burden of disease study focusing on quality of life (in utilities) and cost of illness (in euros). The study is embedded in a randomized controlled trial investigating the effect of perioperative nutrition on postoperative ileus in patients undergoing colorectal surgery (SANICS II trial). Cost and quality of life data collection were done by means of questionnaires given prior to the surgery. The quality of life was measured using EQ-5D-5L questionnaires. The iMTA medical consumption questionnaire (iMCQ) and the iMTA productivity costs questionnaire (iPCQ) were used to identify and measure heal...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - June 15, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis.
Conclusions: PsyMod can be used to examine cost-effectiveness and budget impact of interventions targeting prevention and treatment of FEP and is freely available for academic purposes upon request by the authors. PMID: 31195900 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - June 15, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Tracking the Price of Existing Biologics When Drugs Enter the Market.
Authors: Stiff KM, Cline A, Feldman SR PMID: 31177860 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - June 12, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Navigating Joint HTA, Procurement, and Fair Pricing: Evidence-Based Insights and Practical Recommendations - A meeting report from ISPOR Regional Conference in Warsaw, 2019.
Authors: Inotai A, Németh B Abstract The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) organized its first Central Eastern European regional meeting in 2019 in Warsaw, Poland. The scientific program of the two-day conference covered a broad range of topics presented from the perspective of the region. Specifically, the focus was on cross-country collaboration within different steps of health technology assessment (HTA) and the need for local HTA adaptations in decision-making. Attended by approximately 200 delegates from many countries and by several high level ISPOR leaders, the ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - June 5, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Comparison of the expected rewards between probabilistic and deterministic analyses in a Markov model.
Conclusion: Authors should be aware that probabilistic analysis may lead to increased bias when the evidence is weak. PMID: 31116609 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 23, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Breast Cancer Quality of Life and Health-state Utility at a Brazilian Reference Public Cancer Center.
CONCLUSION: In a context of impairments in mental functioning, sexual enjoyment, symptoms burden, and poor future self-health perspective, breast cancer produced a mean HSU of 0.712. After a period of routine care, there was a small improvement in quality of life, however lower utility estimates were particularly observed in patients with advanced disease and undergoing multiple chemotherapy regimens. PMID: 31106611 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 22, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Health State Utility Values of Osteoporotic Fractures among Korean women.
This study aimed to investigate health state utility values in eight health states related to osteoporosis and osteoporotic fractures using time trade-off (TTO) technique among postmenopausal Korean women. METHODS: Scenarios describing eight health states including osteoporosis and hip, vertebral, post-hip, post-vertebral, ankle, humerus, and wrist fractures were developed and presented to 500 female participants aged 45 to 59 years who were selected with probability proportionate to age group and region for this investigation. Each health states valuation was derived using the trade-off (TTO) technique. 10 years of a ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 18, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management.
We present case studies to complement the different applications of stated-preference methods in clinical drug development and care management. We discuss the applications of preference data to help inform evidence-based patient advocacy, clinical development strategy, operational feasibility, regulator benefit-risk assessments, health technology assessments, and clinical decision-making. Expert commentary: Patient preference studies can serve as a powerful tool to engage patients and their communities as well as quantify the patient voice across different stages of clinical drug development and care management to support ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 10, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
CONCLUSION: The ICER of pasireotide compared to FG SSA was six times higher than the ICER of pegvisomant vs. FG SSA. Pegvisomant is a more cost-effective alternative for the treatment of acromegaly in FG SSA-resistant patients in the Spanish NHS. PMID: 31055976 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 8, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Treatment of immunocompromised patients with suspected invasive fungal infections: economic analysis of diagnostic-driven versus empirical strategies in Algeria and Egypt.
CONCLUSION: Diagnostic-driven compared to empirical therapy may be cost-saving in Algeria and Egypt for the management of immunocompromised patients with persistent neutropenic fever, with no increase in mortality. PMID: 31055986 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 8, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The South African Guidelines for Pharmacoeconomic Submissions' Evidence Requirements Compared with Other African Countries and The National Institute for Health and Care Excellence in England.
CONCLUSIONS: The SAGPS was similar to the EPG, but not as comprehensive as the NICE MG and could be strengthened for decision-making and priority setting. Evidence generation should focus on describing the medicine's targeted disease and current treatment options, and associated cost and outcomes data. PMID: 31056961 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - May 8, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions.
CONCLUSION: This paper discusses the findings of the local experts convened at the workshops relative to their expectations for and views about a national HTA entity within Saudi Arabia. PMID: 31032687 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 30, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Evaluation of Jordanian Healthcare Providers' Knowledge, Attitudes, and Practice Patterns towards Probiotics.
CONCLUSION: The results of this study reveal that HCPs have limited knowledge of probiotics although they have positive attitudes toward them. This is not reflected in their own clinical practice. Additional training and education about probiotics among HCPs are very imperative to enhance patient's care. PMID: 31023117 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 28, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Analysis of Prevalence, Risk factors, and Potential Costs of Unnecessary Drug Therapy in Patients with Chronic Diseases at the Outpatient Setting.
Authors: Arabyat RM, Nusair MB, Al-Azzam SI, Alzoubi KH Abstract BACKGROUND: Patients with chronic diseases require long-term use of medications and usually suffer from multi co-morbidities. Previous research indicated that these patients are at risk for prescription of unnecessary drugs resulting in high economic burden on the patient as well as the society. OBJECTIVE: To determine the prevalence, risk factors, and costs associated with unnecessary drugs in patients with chronic diseases at outpatient settings. METHODS: Clinical and demographic data, unnecessary drug therapy and prices of drugs were obtain...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 26, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost implications of adverse drug event-related emergency department visits - a multi-center study in South Korea.
Authors: Lee MS, Lee JY, Kang MG, Jung JW, Park HK, Kim SH, Lee EK Abstract OBJECTIVES: Adverse drug reactions (ADRs) increase healthcare resource utilization, including that for emergency department (ED) visits. However, cost analyses of ADRs resulting in ED visits are scarce. Therefore, we aimed to estimate the direct medical costs before and after ADR occurrence and analyzed the cost-driving factors. METHODS: The ADR cases were identified by a retrospective review of medical records of patients who visited the ED of three tertiary hospitals in South Korea from July to December 2014. The direct medical cost w...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 25, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A reference set of Health State Utility Values for gambling problem behaviour, a survey of the Australian general population: implications for future healthcare evaluations.
Conclusion Gambling is significantly and negatively associated with HRQoL and HSUVs and the magnitude of this association is determined by the severity of the gambling problem. These data provide insights on inequalities in population health status and can potentially be used to estimate the outcome of health policy interventions in the area of gambling. PMID: 31003582 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 22, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Pharmaceutical expenditure and total healthcare expenditure in OECD countries and China: bidirectional Granger causality on the basis of health level.
CONCLUSION: High-health-level countries should continue to increase the health investment by promoting rational PE growth such as expanding insurance coverage for innovative medicine for health improvement. Low-health-level countries should take optimizing policy to increase health investment in pharmaceutical for medicine accessibility and national health. PMID: 30958724 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 9, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A systematic review and cost analysis of repeat colonoscopies due to inadequate bowel cleansing in five European countries.
CONCLUSIONS: Based on the available evidence, increasing the proportion of people who have adequate bowel cleansing at index colonoscopy will likely have financial benefits in Italy, Spain and the UK. A paucity of data, for France and Germany, limits the robustness of conclusions in these countries. PMID: 30938201 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 3, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Prognostic impact of baseline quality of life status among patients with advanced gastric cancer; results from two randomized studies.
This study represents a pooled analysis from the control arms of two clinical trials (NCT00290966; NCT00678535). Both control arms evaluated fluoropyrimidine/cisplatin combination in the first line treatment of advanced gastric cancer. Univariate and multivariate Cox regression analyses were performed to assess factors affecting overall and progression-free survival. Factors with P
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 24, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
CONCLUSION: Pricing policy remains oriented towards the lowest European prices and reimbursement policy impose cost containment measures. Appraisal of the obligatory Health Technology Assessment Dossiers and pharmacoeconomic analysis is in accordance with world recommendations. Main regulatory issues that still remain to be tackled are the slower entrance of medicines on the national market and lower national prices that often lead to parallel import. PMID: 30900482 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 24, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review.
Authors: Deitelzweig S, Lip GYH PMID: 30870051 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 16, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
CONCLUSIONS: Managed entry agreements are gaining popularity and are viewed as positive schemes by stakeholders, payers and health services, leading to a general increase of accords during the last years. However, there are hardly any studies regarding the impact of RSA post-implementation, a field of great relevance regarding health policies. PMID: 30821532 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - March 4, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary.
CONCLUSION: During the 2 years bid (public procurement procedure), the National Health Insurance Fund Administration managed to reduce the health insurance subsidy paid for the reimbursement of both original and biosimilar G-CSF products by 3.89 billion HUF (14.7 million EUR) or 51.9 % without significant changes in the number of patients having access to treatment. PMID: 30763134 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 16, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Systematic literature review on the economic, humanistic, and societal burden of heart failure in children and adolescents.
Authors: Burch M, Nallagangula TK, Lochlainn EN, Severin T, Thakur L, Jaecklin T, George AT, Solar-Yohay S, Rossano JW, Shaddy RE Abstract INTRODUCTION: Unlike the adult heart failure (HF) patient population, there is scarce of information on the overall burden of HF in the pediatric population across geographies and within different age groups. Areas covered: A systematic review aims to describe and quantify the economic, humanistic, and societal burden of pediatric (age
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 14, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Assessment of risk factors, cost of treatment and therapy outcome in stroke patients: evidence from cross-sectional study.
Authors: Chhabra M, Sharma A, Ajay KR, Rathore MS Abstract INTRODUCTION: Increased prevalence of stroke, and the subsequent increased economic burden on the healthcare system and society is a raising concern in India. Objectives of this study were to assess risk factors, cost of treatment and therapy outcomes in stroke patients. METHODS: This cross-sectional study was conducted in 130 patients of either sex at a government tertiary care hospital of India. Relevant information was collected from available records and through patient interview after permission from ethics committee. National Institute of Health S...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 14, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison.
CONCLUSIONS: Sunitinib or Pazopanib can be considered cost-effective if a 3 GDP per-capita threshold is assumed. The decision between SU or PA is highly sensitive to the price of the drugs, rather than the outcomes. Therefore, the decision might be made based on cost-minimization exercise. PMID: 30758237 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 14, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
CONCLUSION: The choice to treat patients with advanced colorectal cancer using one or the other strategy cannot be based on costs or QoL. PMID: 30739558 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 13, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs.
This study aims to assess the methodological quality of pharmacoeconomic studies of ophthalmic drugs. Areas covered: A systematic search was conducted in Pubmed/Embase until November 2018 to identify full pharmacoeconomic studies evaluating ophthalmic drugs. The quality of studies was evaluated using the British Medical Journal (BMJ) checklist. Quality indicators were evaluated by the Fisher's exact test. Ninety-five studies were included, 50 (52.6%) cost-utility analysis, 28 (29.5%) cost-effectiveness and 17 (17.9%) cost-effectiveness/cost-utility. All studies presented, at least, three methodological limitations. Cost-ut...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 7, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries.
CONCLUSION: This model represents a useful tool for policymakers by providing information regarding the economic and organizational consequences of an early discharge approach in ABSSSI management. PMID: 30714834 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 6, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Proposal for a Regulation on Health Technology Assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.
Authors: Vella Bonanno P, Bucsics A, Simoens S, Martin AP, Oortwijn W, Gulbinovič J, Rothe C, Timoney A, Ferrario A, Gad M, Salem A, Hoxha I, Sauermann R, Kamusheva M, Dimitrova M, Laius O, Selke G, Kourafalos V, Yfantopoulos J, Magnisson E, Joppi R, Jakupi A, Bochenek T, Wladysiuk M, Furtado C, Marković-Peković V, Mardare I, Meshkov D, Fürst J, Tomek D, Cortadellas MO, Zara C, Haycox A, Campbell S, Godman B Abstract INTRODUCTION: In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology assessment and...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - February 1, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Reviewing estimates of the burden in disability-adjusted life years (DALYs) of tick-borne encephalitis in Slovenia.
Authors: Šmit R Abstract INTRODUCTION: Tick-borne encephalitis (TBE) reflects an increasing burden and can affect public health policy. Vaccination could be the most effective option to reduce the disease burden, this review can support national recommendations for TBE vaccination in Slovenia. Areas covered: This burden is relatively high in Slovenia and can be estimated by using an incidence-based disability-adjusted life years (DALYs) methodology. Notably, DALYs have been estimated for Slovenia in various studies. The present study summarizes the main differences and conclusions between two studies that de...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 29, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Evaluating Intensive Care Unit Medication Charges in a Teaching Hospital in Jordan.
Authors: Altawalbeh SM, Abu-Su'ud R, Alefan Q, Momany SM, Kane-Gill SL Abstract BACKGROUND: Intensive Care Unit (ICU) medication costs contribute to a large portion of the total ICU costs. Evaluating ICU drug expenditures is essential for optimal resource use especially in countries with limited resources. Considering the dearth of data regarding ICU medication expenses in the Middle East, we sought to evaluate ICU medication charges at a large academic hospital in Jordan. METHODS: ICU drug charges were extracted from the hospital administration database at King Abdullah University Hospital for 2014-2015 fiscal...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 22, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia.
Authors: Petrou P Abstract INTRODUCTION: End-stage renal disease is associated with significant comorbidity and mortality. Among its implications, hyperphosphatemia constitutes a consistent and independent risk factor. The use of benchmark treatment, low-cost calcium-based binders declined due to a potential calcification effect on coronary arteries. Areas covered: Given the increasing prevalence of end-stage renal disease and the high cost of hyperphosphatemia's new primary modality, the non-calcium based phosphate binders, we set-off to systematically assess the economic evaluations of non-calcium containing phos...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 22, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Exploring knowledge and perceptions on generic drugs of final year pharmacy school students in Greece.
CONCLUSION: It is critical to improve knowledge of and preference for generics amongst healthcare professionals from early on if to build the trust required to increase generic market penetration and achieve measureable savings in pharmaceutical expenditure. PMID: 30658041 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 20, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Prescribing pattern of antihypertensive drugs in two European cohorts: a population-based database study.
CONCLUSIONS: Both prescribing rates and intensity of antihypertensive use were higher in Campania. Pharmacy refill records in cross-national comparisons allow to know the factors influencing variability in prescribing habits with a view to improving prescribing quality. PMID: 30644761 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 17, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Use of Real-World Evidence for Healthcare Decision Making in the Middle East: Practical Considerations and Future Directions.
Authors: Akhras KS, Alsheikh Ali AA, Kabbani S Abstract INTRODUCTION: Real-world evidence (RWE) is increasingly being used in coverage, reimbursement and formulary decisions for medicines globally. Areas covered: The Middle East (ME) region is significantly behind in generating and using RWE in health policy decisions due to several factors that shaped the health sector over the past few decades. The trend, however, is changing due to several factors that are shaping the future of healthcare industry in the region. Among other factors, rising healthcare cost, changing population and disease demographics, increased ...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 12, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies.
Authors: Sensharma A, Yabroff KR Abstract INTRODUCTION: Poor prescription drug adherence is common, jeopardizing the benefits of treatment and increasing the costs of health care in the United States. A frequently reported barrier to adherence is patient out-of-pocket (OOP) costs. Areas Covered: This systematic review examines interventions that address patient cost sharing to improve adherence to prescription drugs and reduce costs of care. Twenty-eight published studies were identified with twenty-two distinct interventions. The majority of papers were published in or after 2010, and nearly a third were published...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 12, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Current Health and Economic Burden of Chronic Diabetic Osteomyelitis.
Authors: Geraghty T, LaPorta G Abstract INTRODUCTION: Diabetic foot ulcer (DFU) prevalence is as high as 25% and 40-80% of DFUs become infected (DFI). About 20% of infected ulcers will spread to bone causing diabetic foot osteomyelitis (DFO). DFU costs Medicare $9-13 billion/year. The most expensive costs associated with DFU are inpatient costs and hospital admissions. DFO costs are driven mostly by surgical procedures. DFU patients have a 3-year cumulative mortality rate of 28% and rates approaching 50% in amputated patients. Areas Covered: This review will summarize the current health and economic burden of DFO c...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - January 11, 2019 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Review of health economic analyses in atopic dermatitis: how diverse is the literature?
Authors: Gutknecht M, Reinert R, Augustin M Abstract INTRODUCTION: Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease. It is associated with a high personal burden of illness and economic consequences. Since AD can occur at any age, and many treatments and prevention options exist, a high diversity of health economic findings can be expected. Areas covered: A literature search was performed in January 2018 with the objective to report on previously published health economic analyses in AD. In total, 89 analyses were identified. Most analyses focused on the cost-of-illness (n = 34; 38%) f...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 31, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Is the National Institute for Health and Care Excellence (NICE) in England more "innovation-friendly" than the Federal Joint Committee (G-BA) in Germany?
Is the National Institute for Health and Care Excellence (NICE) in England more "innovation-friendly" than the Federal Joint Committee (G-BA) in Germany? Expert Rev Pharmacoecon Outcomes Res. 2018 Dec 17;: Authors: Schaefer R, Schlander M Abstract OBJECTIVES: Our study explores whether, and how, different methodological choices are associated with different health technology assessment (HTA) outcomes. We focus on the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) in Germany and the National Institute for Health and Care Excellence (NICE) in England. Both agencies may be considere...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 19, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Valuation of EQ-5D-5L health states: a comparison of seven Asian populations.
CONCLUSION: Utility values of EQ-5D-5L health states differ among Asian populations, suggesting that each health system should establish and use its own value set. PMID: 30523723 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 15, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries.
Authors: Kostaras D, Karampli E, Athanasakis K Abstract INTRODUCTION: During the last years, a significant number economic evaluations of HPV vaccination has been published. Given that cost-effectiveness constitutes an essential part of decision-making with regards to the reimbursement of a health technology, the purpose of this study is to provide a supportive tool to decision-makers regarding the economic efficiency of the introduction of HPV vaccination to national immunization programs. Areas covered: The PubMed database was searched in order to identify cost-effectiveness studies for HPV vaccination. A total o...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 8, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Behind the Subcutaneous Trastuzumab Hype: Evaluation of Benefits and Their Transferability to Central Eastern European Countries.
This study aimed to compare intravenous- (IVT) and subcutaneous trastuzumab (SCT) forms and to explore the transferability of value propositions to Central and Eastern European (CEE) countries. AREAS COVERED: After screening 376 abstracts, 42 articles were included in the final review. Statistical test results were rarely reported, therefore, the similarity of adverse event profiles of SCT and IVT could not be validated. Potential time savings for patients due to subcutaneous administration was not validated in CEE settings, where patient's waiting time for treatment administration is fairly long. Standard patient repo...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 1, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Consumer willingness to pay for a hypothetical zika vaccine in Brazil and the implications.
CONCLUSION: Such discussions can contribute to decision-making about prices once a Zika vaccine becomes available in Brazil alongside other ongoing programmes to control the virus. PMID: 30468095 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 25, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Review of studies reporting actual prices for medicines.
Authors: Mardetko N, Kos M, Vogler S Abstract BACKGROUND: Medicine purchasing and pricing decisions usually rely on officially published prices. Literature has reported evaluations of publicly stated prices. However, due to the frequent use of confidential price arrangements there are indications for paucity of data on actual medicine prices. Therefore, the study aimed to systematically review literature with regard to availability of information on actual medicine prices. Areas covered: The Medline database was searched systematically to identify studies addressing actually paid prices of medicines used in-patient...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 25, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

A scoping review of metamodeling applications and opportunities for advanced health economic analyses.
This study introduces metamodeling and presents results of a review on metamodeling applications in health economics. Areas covered: A scoping review was performed to identify studies that applied metamodeling methods in a health economic context. After search and selection, 13 publications were found to employ metamodeling methods in health economics. Metamodels were used to perform value of information analysis (n=5, 38%), deterministic sensitivity analysis (n=4, 31%), model calibration (n=1, 8%), probabilistic sensitivity analysis (n=1), or optimization (n=1, 8%). One study was found to extrapolate a simulation model to...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 16, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece - the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).
CONCLUSIONS: Acknowledging the limitations of a retrospective analysis, our study confirms previous real-world evidence suggesting that continuing advances in the treatment of mRCC has led to improved outcomes in everyday practice worldwide. Pharmacoeconomic analyses are important for cost effective utilization of emerging novel therapies. PMID: 30417707 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 13, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Mixed effects of restriction strategies in antimicrobial stewardship programs on antimicrobial use in 121 tertiary hospitals in china, 2013-2017.
Authors: Chen H, Liu C, Liu J, Tang Y, Zhang X Abstract BACKGROUND: The research evaluated the impact of intravenous antimicrobial restriction strategy (IARS) on different types of hospitals in China for evidence-based management, for outpatients implemented in 2016. METHODS: Based on panel data on antimicrobial use in 121 tertiary hospitals in Zhejiang, China, segmented regression analysis was used to evaluate the impact of IARS in children's hospitals (CHs), obstetrics and gynecology hospitals (OGHs), women's and children's hospitals (WCHs), traditional Chinese medicine hospitals (TCMHs) and general hospitals...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - November 13, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-utility analysis of outpatient parenteral antimicrobial therapy (OPAT) in the Brazilian national health system.
CONCLUSION: Our economic assessment demonstrated that, in the Brazilian context, OPAT is a cost-saving strategy both for hospitals and the SUS. PMID: 30362845 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 27, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
Authors: Ruggeri M, Rolli FR, Kondili LA, Drago C, De Solda F, Nappi C, Cicchetti A Abstract BACKGROUND: Daclatasvir (DCV) combinated with Sofosbuvir (SOF) has shown good efficacy and safety profile for HCV patients. The aim was to evaluate the cost-effectiveness of DCV/SOF regimen versus HCV alternative treatments for patients who failed to achieve the SVR12 after a first DAA treatment from Italian perspective (PITER cohort). METHODS: A Markov model of HCV chronically infected patients was used to develop two scenarios: 1) DCV+SOF versus Ledipasvir (LDV)+SOF in Genotype (Gt)1 and Gt4; 2) DCV+SOF versus no retr...
Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 25, 2018 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research